The challenges posed by cancer heterogeneity - PubMed

Affiliations

• PMID: 22781679
• DOI: 10.1038/nbt.2294

The challenges posed by cancer heterogeneity

Sangeeta Bhatia et al. Nat Biotechnol. 2012.

Similar articles

• Addressing intra-tumoral heterogeneity and therapy resistance.

  Rybinski B, Yun K. Rybinski B, et al. Oncotarget. 2016 Nov 1;7(44):72322-72342. doi: 10.18632/oncotarget.11875. Oncotarget. 2016. PMID: 27608848 Free PMC article. Review.

• Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.

  Nijman SMB. Nijman SMB. Trends Cancer. 2020 Jun;6(6):454-461. doi: 10.1016/j.trecan.2020.02.016. Epub 2020 Mar 13. Trends Cancer. 2020. PMID: 32460001 Review.

• Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

  Easwaran H, Tsai HC, Baylin SB. Easwaran H, et al. Mol Cell. 2014 Jun 5;54(5):716-27. doi: 10.1016/j.molcel.2014.05.015. Mol Cell. 2014. PMID: 24905005 Free PMC article. Review.

• Drug resistance, epigenetics, and tumor cell heterogeneity.

  Hoey T. Hoey T. Sci Transl Med. 2010 Apr 21;2(28):28ps19. doi: 10.1126/scitranslmed.3001056. Sci Transl Med. 2010. PMID: 20410528

• Intra-tumor heterogeneity from a cancer stem cell perspective.

  Prasetyanti PR, Medema JP. Prasetyanti PR, et al. Mol Cancer. 2017 Feb 16;16(1):41. doi: 10.1186/s12943-017-0600-4. Mol Cancer. 2017. PMID: 28209166 Free PMC article. Review.

Cited by

• Importance of Incorporating the Perspectives of People with Cancer into Oncology Education: A Scoping Review.

  Dutt H, Dean A, Kamal RS, Allan AL. Dutt H, et al. J Med Educ Curric Dev. 2023 Dec 17;10:23821205231219394. doi: 10.1177/23821205231219394. eCollection 2023 Jan-Dec. J Med Educ Curric Dev. 2023. PMID: 38116493 Free PMC article.

• Large-scale patterning of single cells and cell clusters in hydrogels.

  Gong X, Mills KL. Gong X, et al. Sci Rep. 2018 Mar 1;8(1):3849. doi: 10.1038/s41598-018-21989-4. Sci Rep. 2018. PMID: 29497104 Free PMC article.

• Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression.

  Denisov EV, Litviakov NV, Zavyalova MV, Perelmuter VM, Vtorushin SV, Tsyganov MM, Gerashchenko TS, Garbukov EY, Slonimskaya EM, Cherdyntseva NV. Denisov EV, et al. Sci Rep. 2014 Apr 16;4:4709. doi: 10.1038/srep04709. Sci Rep. 2014. PMID: 24736530 Free PMC article.

• The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy.

  Masunaga S, Sakurai Y, Tanaka H, Tano K, Suzuki M, Kondo N, Narabayashi M, Nakagawa Y, Watanabe T, Maruhashi A, Ono K. Masunaga S, et al. Springerplus. 2014 Mar 7;3:128. doi: 10.1186/2193-1801-3-128. eCollection 2014. Springerplus. 2014. PMID: 25674433 Free PMC article.

• Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment.

  Zhang P, Lock LL, Cheetham AG, Cui H. Zhang P, et al. Mol Pharm. 2014 Mar 3;11(3):964-73. doi: 10.1021/mp400619v. Epub 2014 Jan 29. Mol Pharm. 2014. PMID: 24437690 Free PMC article.

References

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database